Glucotrack restates Lokahi merger pro forma for 1-for-15 reverse split; H1 2026 pro forma net loss $19.7M

Glucotrack, Inc.

Lokahi merger closed July 14, 2026; 5,323,013 common-equivalent shares issued, valued at $33.33M ($6.261/share).
Purchase price allocated to $25.4M in-process R&D/intangibles and $14.67M goodwill; liabilities assumed $9.24M.
Pro forma H1 2026 net loss $19.70M (no revenue); FY2025 pro forma net loss $28.14M, EPS loss $236.97.
Bridge: $4.45M gross (face $5.71M, 22% OID, 8% coupon, due 4/14/27) plus $3.5M follow-on (due 5/4/27).
1-for-15 split effective Aug 28, 2026; ELOC allows up to $50M of stock sales over 3 years, none sold.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.